SOL Surges 8%, With Its CME Futures Volume Hitting an All-Time High
Solana's SOL token
Per a post on X earlier today by crypto analytics firm Glassnode, CME futures volume for SOL hit an all-time high of 1.75 million contracts, reflecting an increase in institutional interest. This marked the highest volume level since the exchange introduced SOL futures in March, signaling aggressive positioning by sophisticated market participants as price approached the $145 zone.
In a separate development with longer-term significance, Kazakhstan's government issued a press release on May 30 announcing the creation of the Solana Economic Zone Kazakhstan (SEZ KZ), the first such initiative in Central Asia built on Solana’s blockchain. The launch event took place in Astana with support from the Solana Foundation and government agencies. According to the Ministry of Digital Development, Innovation and Aerospace Industry, the SEZ will serve as a testbed for asset tokenization, blockchain engineering education, and foreign startup onboarding.
The SEZ initiative includes three strategic pillars:
- Tokenized Capital Markets: A pilot program with AIX, Solana Foundation, Jupiter, and Intebix aims to introduce tokenized financial instruments into Kazakhstan’s infrastructure.
- Web3 Talent Development: A nationwide blockchain education initiative will be launched in partnership with universities and Astana Hub.
- Startup Onboarding: With support from Forma, the country plans to attract international Web3 firms through infrastructure access, regulatory clarity, and business incentives.
Technical Analysis Highlights
- SOL gained 7.63%, climbing from $133.55 to $145.47 within a $15.94 range.
- The sharpest rally occurred at 22:00, when price spiked to $146.90 on 3.92M volume.
- A high-volume support level was established at $132.43 during the 17:00 hour.
- SOL entered a consolidation zone between $143 and $146 with resistance at $146.55.
- A V-shaped recovery followed a dip from $144.88 to $143.59.
- Strong support emerged at $143.60 with 38,097 SOL volume at 13:53.
- A short-term support band formed between $143.60 and $143.80.
- Immediate resistance was observed at $144.30.
Disclaimer: Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
